Latest Health News

BCI Minerals reports significant progress at its Mardie Salt Operation and Potash Project with near-complete pond inundation and major construction milestones achieved in the September 2025 quarter.

Salter Brothers Emerging Companies Limited has announced a further 12-month extension of its on-market share buy-back program, allowing the company to repurchase up to 8.45 million shares to maintain capital management flexibility and enhance shareholder value.

Black Canyon Limited reported a robust cash position of A$11.6 million at the end of September 2025, supported by a strong equity raise that extends its funding runway to nearly three years.

Avecho Biotechnology has raised $2.5 million from institutional investors to fast-track manufacturing and regulatory preparations for its CBD TPM capsule amid ongoing Phase III trials.

Anatara Lifesciences reports steady progress in its anti-obesity pre-clinical studies with results expected by year-end, while preparing its GaRP gastrointestinal health data for publication amid ongoing commercial talks. The company also announces a key board appointment and a $1.2 million capital raise.

Lumos Diagnostics reported steady quarterly revenue with a 300% surge in product sales, driven by its flagship FebriDx® test. The company inked a landmark US$317 million exclusive U.S. distribution agreement and awaits FDA feedback on its CLIA waiver application.

Audeara Ltd has reported a remarkable 111% revenue increase in Q1 FY26, driven by strong growth in its technology division and key international partnerships in China and Japan. The company is advancing towards cashflow breakeven with improved cash management and expanding global reach.

Cochlear Limited reports steady FY25 financials alongside the launch of its innovative Nucleus Nexa cochlear implant system, setting the stage for projected double-digit profit growth in FY26.

Control Bionics has successfully raised $0.6 million through a shortfall placement, reinforcing investor confidence as it accelerates commercialisation of its neurotechnology in assistive communication and emerging sports markets.

Australian Clinical Labs has announced a 12-month on-market share buy-back program targeting up to 10% of its shares, aiming to enhance shareholder returns without compromising its financial strength.

Regis Resources reported a solid September quarter with 90.4koz gold production and a $158 million increase in cash and bullion. Key underground projects at Garden Well Main and Rosemont Stage 3 began ore production, supporting steady FY26 guidance.

Australis Oil & Gas reported a modest dip in production volumes for Q3 2025 but offset this with higher realised oil prices and disciplined cost management. The company remains focused on securing a development partner to unlock the full potential of its Tuscaloosa Marine Shale assets.